Surgical treatment of patients with intermediate-terminal pancreatic cancer.
OBJECTIVE
To investigate the surgical treatment of patients with intermediate-terminal pancreatic cancer.


METHODS
A retrospective analysis was made of the clinical data of 163 patients with intermediate-terminal pancreatic cancer who were surgically treated between August 1994 and August 2003.


RESULTS
A total of 149 patients underwent palliative surgery. The mortality rate of those who underwent cholecystojejunostomy alone was 14.2%, the icterus or cholangitis recurrence rate was 61.9% with an average survival period of 7.1 mo. The mortality rate for those who received hepatic duct-jejunostomy (HDJS) was 5.7%, the icterus or cholangitis recurrence rate was 6.8% with an average survival period of 7.1 mo. But 31.8% of the patients developed duodenum obstruction within 6 mo after the surgery, six of seven patients with severe pain were given peri-abdominal aorta injection with absolute alcohol and their pain was alleviated. The other patients underwent percutaneous transhepatic cholangial drainage (PTCD) and their icterus index returned to normal level within 40 d with an average survival period of 7.5 mo.


CONCLUSIONS
Roux-en-Y HDJS combined with prophylactic gastrojejunostomy is recommended for patients with intermediate-terminal pancreatic cancer, and biliary prosthesis can partly relieve biliary obstruction in a short term.
Liu
Yu-Bin
YB
Department of Hepatobiliary Surgery, Guangdong Provincial People's Hospital, Guangzhou 510080, Guangdong Province, China. benson_lau@hotmail.com
Huang
Liang
L
Xian
Zhi-Yong
ZY
Jian
Zhi-Xiang
ZX
Ou
Jin-Rui
JR
Liu
Zi-Xian
ZX
D000328:Adult; D000368:Aged; D013505:Digestive System Surgical Procedures; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000601:surgery*; D012189:Retrospective Studies